Rosenholm, Jessica

Jessica Rosenholm
Pharmaceutical Sciences Laboratory, Åbo Akademi University, Turku, Finland

Biography:
Jessica Rosenholm holds a docentship in biomedical nanotechnology at Åbo Akademi University, Finland, from where she also received her MSc(Tech) degree in chemical engineering in 2002. Her doctorate period included a four-year funded position in the national Biomaterials and Tissue Engineering Graduate School, from which she graduated her DSc(Tech) degree in 2008. Her thesis work “Modular Design of Mesoporous Silica Materials: Towards Multifunctional Drug Delivery Systems” has been awarded national and international prizes, e.g. the Akzo Nobel Nordic Research Prize 2009 for best doctoral thesis and research activity in colloid and surface science in the Nordic countries. In 2009-2010 she spent a postdoctoral period at the Nano Biomedical Research Centre, Med-X Research Institute, Shanghai Jiao Tong University in China. Since returning to Finland in 2010, she heads her own group, the BioNanoMaterials group. The group’s activities are centered on the development of nanomedicines for drug delivery and/or imaging, for the enabling of a variety of diagnostic and therapeutic applications. The designed systems are largely based on mesoporous silica and its composite nanostructures. Since 1.1.2015 she is appointed professor in pharmaceutical development at the Pharmaceutical Sciences Laboratory, Faculty of Science and Engineering, Åbo Akademi University (www.pharmscilab.fi). Currently the group is further involved in formulating the already developed nanosystems into different dosage forms including dermal patches, antibacterial coatings and varying 2D/3D printed formulations e.g. for tissue engineering.

Lecture: 
Multimodal nanoantibiotics for synergistic modes of action against infectious diseases and for biofilm treatment

The current global threat of increasing antimicrobial resistance (AMR), termed the “post-antibiotic era” by the WHO, as well as the recalcitrant nature of biofilm-associated infections call for the development of alternative strategies to treat bacterial diseases. Nanoparticles (NPs) have been recognized as one of the emerging and promising platforms in this respect, due their unique physical and chemical properties, which provide fine-tuning of their interactions with bacteria. Antibacterial NPs, “nanoantibiotics”, can be designed to treat infectious diseases more effectively than conventional antibiotics by making use of their advantageous properties known from other nanomedical fields. These include improved pharmacokinetics of incorporated drugs, site-targeted delivery, sustained or controlled release, improved drug stability and dissolution, and so forth. The perhaps most advantageous property of nanoantibiotics in combating AMR is the possibility to construct multimodal NPs, providing synergistic actions [1] while making it difficult for bacterial cells to become resistant. Namely, the thus incorporated multiple simultaneous mechanisms of action would, likewise, require multiple simultaneous gene mutations in the same bacterial cell for AMR to develop [2]. We have constructed nanoantibiotics out of organic & inorganic components composed of an antibacterial core material (metal or metal oxide) surrounded by a mesoporous silica shell in which antibiotic drugs are incorporated, coated with an antibacterial polymeric layer. The extent of in vitro bacterial growth inhibition caused by the produced nanoantibiotics has been investigated, whereas Drosophila melanogaster (fruit fly) has been used as an in vivo animal model to study the antibacterial activity of the nanoantibiotics in the gastro-intestinal tract. The observed results revealed that multiple antibacterial constructs in the designed system can improve the antibacterial activity in a synergistic fashion.

[1] Şen Karaman, D., Sarwar, S., Desai, D. et al. J. Mater. Chem. B, 4, 3292-3304 (2016)
[2] Wang, L., Hu, C., Shao, L. Int. J. Nanomedicine, 12, 1227–1249 (2017)